Determine the necessary mass, volume, or concentration for preparing a solution.
BDP9066 - 10mM in DMSO , CAS No.2226507-04-4
Disponibile su ordine
GRADE & PURITY 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
224,000+ prodotti di ricerca · Triple ISO certified · COA & SDS Disponibile per ogni prodotto · Spedizione lo stesso giorno su articoli in magazzino
Why this grade
10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 1 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Panoramica
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC 50 of 64 nM for MRCKβ in SCC12 cells, K i values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
In Vitro
BDP9066 shows antiproliferative effects with greatest activity in hematologic cancer cells. BDP9066 inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BDP9066 topical application significantly decreases phosphorylated MRCKα S1003 staining and tumor volumes . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
IC50& Target:IC50: 64 nM (MRCKβ in SCC12 cells), Ki: 0.0136 nM/0.0233 nM (MRCKα/β)
Specifications
Specifiche e purezza
10mM in DMSO
Meccanismi biochimici e fisiologici
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC 50 of 64 nM for MRCKβ in SCC12 cells, K i values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeu
Condizioni di conservazione di stoccaggio
Store at -80°C
Spedito in
Dry ice packs + Cold packs
Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.
Tipo di azione
INHIBITOR
Nomi e identificatori
| PubChem CID | 132275018 |
|---|---|
| Termini MeSH | (6S)-8-(3-(4-Pyrimidinyl)-7H-pyrrolo(2,3-b)pyridin-4-yl)-1,8-diazaspiro(5.5)undecane;1,8-Diazaspiro(5.5)undecane, 8-(3-(4-pyrimidinyl)-7H-pyrrolo(2,3-b)pyridin-4-yl)-, (6S)-;BDP9066 |
| Peso molecolare | 348.44 |
Documentazione
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificati (CoA, COO, BSE/TSE e tabella di analisi)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Citations of This Product
Riferimenti
| 1. Sufang Xu, Xin Zhang, Jingru Sun, Man Qin, Huarong Du, Bing Luo. (2026) Macrophage-Derived Transcriptional Signatures Predict Prognosis and Drug Sensitivity in Thyroid Cancer: Integrative Analysis and Experimental Validation of SMYD3. ImmunoTargets and Therapy, [PMID:] [10.2147/ITT.S565624] |
Calcolatori di soluzioni
Recensioni
Recensioni dei clienti
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.